Discussion page for Arch Therapeutics (ARTH)This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
I hope I can post an off topic Biotec I found this a few months ago and now it is beginning to get interesting. IIRC Biotec devices have shorter trial sizes. They spent 6 years with one of our National Labs developing an iron particle small enough to be coated with a biotec medium that attaches to a cancerous growth. $ASX:IBX – Imagion Biosystems Receives FDA Breakthrough Device Designation “Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announced that it has received notification from the Center for Devices… Read more »
Per ARTH 10Q on timing of CE mark: “Given the recent changes in the governing rules and the impact of Brexit, the review process has taken longer than anticipated. We now currently expect that the review process to be completed this fall.”
$ARTH – Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
https://ir.archtherapeutics.com/press-releases/detail/527
AC5 keeps getting better “Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body”. CE approval this Fall maybe not much longer.
ARTH long
$ARTH Long A nice press release – so a question for you all about their statement – “As a result, we currently expect the review process to be completed this fall, and we anticipate our next update to coincide with a definitive and material announcement.” So, what does TN mean by “our next update? ” Is that the monthly update they seem to make about the company or the next time they talk about the CE application? I really like this part “to coincide with a definitive and material announcement”. That seems to be really a positive statement that portends… Read more »
I’m not aware of any scheduled updates I’ve signed up for their newsletters, as I do with most all companies I’ve invested in, there are no scheduled updates that I’m aware of. I would think that they are working on one because this is the first I’ve heard of the antimicrobial and that needs to be elaborated on. I won’t guess as to which comes first CE approval or more antimicrobial data. Right now I’m just hoping it’s before November there are others more informed than I.
The definitive material announcement is going to be more dilution and more delays.
So are you going to sell the stock?
I don’t know, but I think anyone who’s been invested in this stock for years like I have should be concerned. How are you feeling about their financial position and their ability to raise money now in comparison to the post below from you a year ago, do you think this is still on track?: I worry a lot more about biotech companies that can’t raise money than those that can. This $4.5 million will carry ARTH into the December 2019 quarter, so we will get the results of the sensitization study, the 510(k) filing, the CE Mark filing, the… Read more »
Pretty much the same. The (unnecessary) sensitization study was good, the 510(k) was filed on time, the CE Mark was filed on time, the 510(k) was approved, the CE Mark approval is next, and the IND will be filed before he needs to raise money again.
Given the CE Mark delay, I don’t know if there’s time to sign a European distribution deal before he needs to raise money. He may squeeze by with warrant exercise proceeds if the CE Mark pops the stock enough.
In the meantime these Yahoo!’s collect $500,000 salaries. Send out a sentence or two every few months and ask for more money every few years.sheesh people. ???
Quite a good summary of Arch Therapeutics in Seeking Alpha
https://seekingalpha.com/article/4285493-examining-next-arch-therapeutics
yours, Finn